A Phase III Trial of Fluoropyrimidines (FP) Plus Bevacizumab (BEV) vs. Bev Alone, or No Treatment as Maintenance Strategy, Following a Standard Combination of FP, Oxaliplatin (OX), and Bev as First-Line Treatment for Patients with Metastatic Colorectal Cancer (MCRC): AIO KRK 0207
Keyword(s):
Keyword(s):
2012 ◽
Vol 30
(15_suppl)
◽
pp. TPS3639-TPS3639
Keyword(s):
Keyword(s):
2012 ◽
Vol 30
(15)
◽
pp. 1755-1762
◽
2004 ◽
Vol 22
(14_suppl)
◽
pp. 3517-3517
◽
Keyword(s):
2004 ◽
Vol 22
(14_suppl)
◽
pp. 3517-3517
◽
Keyword(s):
2005 ◽
Vol 23
(16_suppl)
◽
pp. 3516-3516
◽
Keyword(s):
2010 ◽
Vol 28
(15_suppl)
◽
pp. 3541-3541
◽
Keyword(s):
2006 ◽
Vol 6
(4)
◽
pp. 261-264
◽
Keyword(s):